Why the study?
Recurrences of adverse thrombotic events remain a major clinical burden in dyslipidemia despite advancements in antithrombotic therapies, warranting a reassessment of therapeutic approaches based on platelet signaling mechanisms.
This review provides an overview of the mechanisms driving pathologic thrombosis in dyslipidemia and suggests revisiting antithrombotic approaches to address the residual clinical burden.
Answers are grounded in this paper and cite their sources.
May support refined antithrombotic strategies in dyslipidemia; leaves open need for prospective validation before practice change.
The risks for adverse thrombotic events, including myocardial infarction, stroke, and deep vein thrombosis, are markedly increased in dyslipidemia and other metabolic disorders and are the major cause of death worldwide. Recent evidence points out that increased thrombotic risk in dyslipidemia is mediated by platelets circulating in a pre-activated state. The mechanisms of platelet reactivity in this setting are multifaceted including platelet activation by classic agonist receptor signaling as well as platelet sensitization by pattern recognition receptors. Elevated platelet counts in dyslipidemia due to dysregulation in hematopoiesis also contribute to the overall thrombotic phenotype. Despite recent advancements in antiplatelet and anticoagulation therapies, recurrences of adverse thrombotic events remain to be a large clinical burden. In the light of new knowledge, understanding mechanisms that drive pathologic thrombosis in dyslipidemia, the antithrombotic approach shall be revisited. Here, we discuss potential therapeutic avenues based on the overview of platelet signaling mechanisms that contribute to a prothrombotic phenotype in dyslipidemia.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: